These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

142 related items for PubMed ID: 24452425

  • 41. Differential host immune responses to epidemic and endemic strains of Shigella dysenteriae type I.
    Sayem MA, Ahmad SM, Rekha RS, Sarker P, Agerberth B, Talukder KA, Raqib R.
    J Health Popul Nutr; 2011 Oct; 29(5):429-37. PubMed ID: 22106748
    [Abstract] [Full Text] [Related]

  • 42. [Studies of crossed immunity between different serotypes of dysentery bacilli and the keratoconjunctivitis-positive, lactoso-negative strain 47552 deprived of Shigella agglutinogen].
    Ciufeco C.
    Arch Roum Pathol Exp Microbiol; 1969 Oct; 28(2):389-94. PubMed ID: 4925072
    [No Abstract] [Full Text] [Related]

  • 43. Antibodies to shiga holotoxin and to two synthetic peptides of the B subunit in sera of patients with Shigella dysenteriae 1 dysentery.
    Levine MM, McEwen J, Losonsky G, Reymann M, Harari I, Brown JE, Taylor DN, Donohue-Rolfe A, Cohen D, Bennish M.
    J Clin Microbiol; 1992 Jul; 30(7):1636-41. PubMed ID: 1629317
    [Abstract] [Full Text] [Related]

  • 44.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 45.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47. [Local immunity in the parenteral immunization of guinea pigs with a ribosomal dysentery vaccine].
    Liubinskaia MM, Rukhadze EZ, Chernokhvostova EV, Levenson VI.
    Zh Mikrobiol Epidemiol Immunobiol; 1985 Jul; (7):55-9. PubMed ID: 3901625
    [Abstract] [Full Text] [Related]

  • 48. Safety and immunogenicity of SC599, an oral live attenuated Shigella dysenteriae type-1 vaccine in healthy volunteers: results of a Phase 2, randomized, double-blind placebo-controlled trial.
    Launay O, Sadorge C, Jolly N, Poirier B, Béchet S, van der Vliet D, Seffer V, Fenner N, Dowling K, Giemza R, Johnson J, Ndiaye A, Vray M, Sansonetti P, Morand P, Poyart C, Lewis D, Gougeon ML.
    Vaccine; 2009 Feb 18; 27(8):1184-91. PubMed ID: 19135496
    [Abstract] [Full Text] [Related]

  • 49. [A morphological evaluation of the protective properties of noninvasive recombinant strains of Shigella].
    Polotskiĭ IuE, Efremov VE, Bondarenko VM, Nastichkin IA, Belov AG, Kan IM, Smirnova GV, Romanova IuM.
    Zh Mikrobiol Epidemiol Immunobiol; 1993 Feb 18; (2):15-23. PubMed ID: 8059565
    [Abstract] [Full Text] [Related]

  • 50. Development of recombinant vaccine candidate molecule against Shigella infection.
    Chitradevi STS, Kaur G, Sivaramakrishna U, Singh D, Bansal A.
    Vaccine; 2016 Oct 17; 34(44):5376-5383. PubMed ID: 27591952
    [Abstract] [Full Text] [Related]

  • 51. Semiquantitative estimation of Shigella antigen-specific antibodies: correlation with disease severity during shigellosis.
    Islam D, Wretlind B, Hammarström L, Christensson B, Lindberg AA.
    APMIS; 1996 Oct 17; 104(7-8):563-74. PubMed ID: 8920810
    [Abstract] [Full Text] [Related]

  • 52. Detection of antibodies to Shigella lipopolysaccharide in urine after natural Shigella infection or vaccination.
    Cohen D, Orr N, Robin G, Slepon R, Ashkenazi S, Ashkenazi I, Shemer J.
    Clin Diagn Lab Immunol; 1996 Jul 17; 3(4):451-5. PubMed ID: 8807212
    [Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55. Serum IgG antibodies to Shigella lipopolysaccharide antigens - a correlate of protection against shigellosis.
    Cohen D, Meron-Sudai S, Bialik A, Asato V, Goren S, Ariel-Cohen O, Reizis A, Hochberg A, Ashkenazi S.
    Hum Vaccin Immunother; 2019 Jul 17; 15(6):1401-1408. PubMed ID: 31070988
    [Abstract] [Full Text] [Related]

  • 56. Characterization of a novel fusion protein from IpaB and IpaD of Shigella spp. and its potential as a pan-Shigella vaccine.
    Martinez-Becerra FJ, Chen X, Dickenson NE, Choudhari SP, Harrison K, Clements JD, Picking WD, Van De Verg LL, Walker RI, Picking WL.
    Infect Immun; 2013 Dec 17; 81(12):4470-7. PubMed ID: 24060976
    [Abstract] [Full Text] [Related]

  • 57. Oral immunization with LacVax® OmpA induces protective immune response against Shigella flexneri 2a ATCC 12022 in a murine model.
    Yagnik B, Sharma D, Padh H, Desai P.
    Vaccine; 2019 May 21; 37(23):3097-3105. PubMed ID: 31047673
    [Abstract] [Full Text] [Related]

  • 58. Quantitative analysis of IgG class and subclass and IgA serum response to Shigella sonnei and Shigella flexneri 2a polysaccharides following vaccination with Shigella conjugate vaccines.
    Robin G, Keisari Y, Slepon R, Ashkenazi S, Cohen D.
    Vaccine; 1999 Aug 06; 17(23-24):3109-15. PubMed ID: 10462247
    [Abstract] [Full Text] [Related]

  • 59.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 60.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.